RecruitingNot ApplicableNCT06849037
Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo
and Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Who Will be Treated With Prophylactic Antibiotics Zinacef vs. Placebo
Sponsor
Western Galilee Hospital-Nahariya
Enrollment
182 participants
Start Date
Feb 18, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria2
- singleton pregnancy at term
- meconium-stained amniotic fluid
Exclusion Criteria4
- Intrauterine fetal death
- GBS carriers
- zinacef allergy
- antibiotic treatment for other indication
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGzinacef tretment
prophylactic antibiotic treatment with zinacef
OTHERPlacebo
I.V SALINE 100 CC X3/d
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06849037